Skip to content
RSS

Purdue Pharma Sentenced to $5.5 Billion, Unlocking Opioid Settlement

U.S. District Judge Madeline Cox Arleo sentenced Purdue Pharma LP to $5.5 billion in criminal penalties on April 28 in federal court in Newark, New Jersey, imposing a $3.544 billion criminal fine and $2 billion in criminal forfeiture on the opioid manufacturer [1]. The sentence resolves the criminal docket stemming from Purdue's 2020 guilty plea and clears the final major legal hurdle before the company dissolves and restructures as a nonprofit public-benefit entity [1][2].

Purdue pleaded guilty in 2020 to three felony counts, including conspiring to defraud the Drug Enforcement Administration and paying illegal kickbacks to physicians to increase OxyContin prescriptions [1]. The charges arose from conduct the government alleged drove over-prescription of the company's flagship opioid product and contributed materially to the broader opioid epidemic. The plea was entered in the District of New Jersey, and sentencing was held before Judge Arleo [1].

Under the terms of the plea agreement, most of the $5.5 billion in assessed penalties will go uncollected as a practical matter. The Department of Justice will collect $225 million directly, while Purdue directs its remaining assets, totaling approximately $7.4 billion, into a bankruptcy settlement structured to compensate opioid victims, fund addiction treatment, and support public-health abatement programs [1][2]. Deputy Attorney General Todd Blanche and Purdue restructuring advisor Steve Miller were identified as key figures in the proceedings [1]. The sentencing hearing included testimony from individuals affected by opioid addiction, offering victim perspectives on the company's conduct [2].

The $7.4 billion bankruptcy settlement had been subject to years of litigation, including a 2023 U.S. Supreme Court ruling that vacated an earlier bankruptcy plan that had shielded members of the Sackler family, Purdue's controlling owners, from civil liability without their personal filing for bankruptcy [2]. The revised settlement preserved a path to resolution while removing that contested liability shield. The criminal sentencing now formally separates the criminal and civil tracks and allows the bankruptcy distribution process to proceed.

Purdue is expected to complete its dissolution and transition to a nonprofit public-benefit company as assets move through the bankruptcy estate to creditors, state governments, and victim compensation programs [1][2]. No further criminal proceedings against the company are anticipated. Whether any individuals face separate accountability remains a distinct question the current record does not resolve.

References

[1]DOJ Office of Public Affairs. (2026, April 28). Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies. https://www.justice.gov/opa/pr/opioid-manufacturer-purdue-pharma-sentenced-fraud-and-kickback-conspiracies
[2]CNBC. (2026, April 29). Purdue Pharma receives $5.5 billion sentence, paving way for opioid settlement. https://www.cnbc.com/2026/04/29/purdue-pharma-receives-5point5-billion-sentence-paving-way-for-opioid-settlement.html

Latest Articles

Discussion

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top
Search